Opthea (ASX:OPT) said there remains material uncertainty as to its ability to continue as a "going concern" as it continues to be in active negotiations with its development funding agreement investors, according to a Monday Australian bourse filing.
The management plans to hold an investor call to discuss the phase three trial results and the next steps of the firm once the negotiations with the investors have been concluded.
In the same filing, the company said Julia Haller, Susan Orr, Quinton Oswald, and Anshul Thakral resigned as directors, effective Monday, to streamline the governance in the wake of negative phase three trial results and a 65% reduction in workforce.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。